Attenuation of Cardiac Autonomic Neuropathy by Escin in Diabetic Rats.
Animals
Antioxidants
/ pharmacology
Autonomic Nervous System Diseases
/ drug therapy
Catalase
/ metabolism
Diabetes Mellitus, Experimental
/ complications
Diabetic Neuropathies
/ drug therapy
Escin
/ pharmacology
Glutathione
/ metabolism
Heart
/ innervation
Heart Diseases
/ drug therapy
Heart Rate
/ drug effects
Hemodynamics
/ drug effects
Male
Malondialdehyde
/ metabolism
Matrix Metalloproteinase 9
/ blood
Neuroprotective Agents
/ pharmacology
Oxidative Stress
/ drug effects
Rats, Sprague-Dawley
Superoxide Dismutase
/ metabolism
Vagus Nerve
/ pathology
Aesculus hippocastanum
Aesculus indica
Diabetic complications
Diabetic neuropathy
Escin
Journal
Pharmacology
ISSN: 1423-0313
Titre abrégé: Pharmacology
Pays: Switzerland
ID NLM: 0152016
Informations de publication
Date de publication:
2021
2021
Historique:
received:
27
05
2020
accepted:
19
06
2020
pubmed:
3
9
2020
medline:
24
6
2021
entrez:
3
9
2020
Statut:
ppublish
Résumé
Cardiac autonomic neuropathy (CAN) is a least diagnosed complication of diabetes. Inflammation and oxidative stress play a crucial role in the pathophysiology of cardiomyopathy and neuropathy. Escin has anti-inflammatory activity and antioxidant activity. Hence, the present study was designed to evaluate the effect of escin in the management of CAN. Diabetes was induced in Sprague Dawley rats with streptozotocin (STZ). Diabetic animals were randomized in different groups after 6 weeks. Animals in the diabetic control group received no treatment, while animals in other groups received escin at dose 5, 10, and 20 mg/kg for 4 weeks. One group was kept as normal control. Various parameters like basic hemodynamic parameters, heart rate variability (HRV), oxidative stress parameters, and matrix metalloproteinase 9 (MMP-9) were assessed at the end of study. Escin significantly normalized hemodynamic parameters and HRV as compared to diabetic animals. Escin significantly reduced the malondialdehyde level and significantly increased reduced glutathione, catalase and superoxide dismutase levels in diabetic animals. Escin treatment significantly reduced plasma MMP-9 level in diabetic rats. The improvement in the studied parameters was found mainly with administration of higher doses of escin (10 and 20 mg/kg). The escin treatment mitigates CAN in diabetic rats. The results of study indicate that escin can be useful option for management of CAN.
Identifiants
pubmed: 32877906
pii: 000509730
doi: 10.1159/000509730
doi:
Substances chimiques
Antioxidants
0
Neuroprotective Agents
0
Malondialdehyde
4Y8F71G49Q
Escin
6805-41-0
Catalase
EC 1.11.1.6
Superoxide Dismutase
EC 1.15.1.1
Matrix Metalloproteinase 9
EC 3.4.24.35
Mmp9 protein, rat
EC 3.4.24.35
Glutathione
GAN16C9B8O
Types de publication
News
Langues
eng
Sous-ensembles de citation
IM
Pagination
211-217Informations de copyright
© 2020 S. Karger AG, Basel.